Moscow- The Russian authorities have agreed with the Chinese company Shenzhen Yuanxing Gene-tech to produce 60 million doses of the Russian Sputnik V vaccine in China, the Russian Direct Investment Fund (FIDR) reported Monday in a statement.
“The FIDR and one of China’s leading biotechnology companies, Shenzhen Yuanxing Gene-tech, have agreed to cooperate for the production of 60 million doses of the world’s first registered covid vaccine,” the document states.
The fund, in charge of promoting the sale of Sputnik V, specifies that the agreement will allow more than 30 million people to be vaccinated.
“The start of commercial production is expected in May,” adds the FIDR.
So far, Sputnik V has been recorded in 57 countries with a total population of 1.5 billion people.
As Alexandr Ginzburg, director of the Russian Gamaleya Research Center, which developed Sputnik V, pointed out in an interview today, the manufacturers of the preparation want to supply it “to another 50 countries.”
In addition to Sputnik V, which is 91.6% effective and priced per dose of less than $ 10, Russia has registered two other vaccines.